Rx and Dx: Imperfect companions?
This article was originally published in Scrip
Executive Summary
Pharma and diagnostics firms can be reluctant bedfellows when it comes to companion diagnostics. Madeleine Armstrong wonders if the current typical deal structure leaves a lot to be desired.